Lipid-lowering agents and new onset diabetes mellitus

被引：29

作者：

Athyros, Vasilios G. ^{[2
,3
]}

Tziomalos, Konstantinos ^{[4
]}

Karagiannis, Asterios ^{[2
,3
]}

Mikhailidis, Dimitri P. ^{[1
]}

机构：

[1] UCL, Sch Med, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England

[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med,Atherosclerosis Unit, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece

[3] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med,Metab Syndrome Outpatient Unit, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece

[4] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Propedeut Dept Internal Med 1, GR-54006 Thessaloniki, Greece

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 12期

关键词：

colesevelam; dyslipidaemia; new-onset diabetes; nicotinic acid; statins; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL; VITAMIN-D; CARDIAC OUTCOMES; HYPERCHOLESTEROLEMIC PATIENTS; HYPERTENSIVE PATIENTS; INSULIN SENSITIVITY; GREEK ATORVASTATIN; ADVANCED GLYCATION;

D O I：

10.1517/14656566.2010.489553

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM). However, statin induced cardiovascular disease (CVD) risk reduction is greater in patients with DM than in non-diabetic patients in several survival studies. Thus, statin treatment outweighs any potential increase in CVD risk related to NODM and in high-risk Caucasian patients present clinical practice should not change. However, the risk/benefit ratio of treatment might not be as favourable in subjects with propensity to develop DM such as the elderly and in subjects of Asian ethnicity. Colesevelam was shown to improve both glycaemic control and lipid profile in inadequately controlled T2DM and might reduce the risk for NODM. There are no data on the incidence of NODM in fibrate-treated non-diabetic patients. Prospective studies are needed to clarify these issues.

引用

页码：1965 / 1970

页数：6

共 59 条

[1]

ADIT A, 2009, ARCH INTERN MED, V169, P626

[2] Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients [J].

Ahmed, Waqas ;

Khan, Naseer ;

Glueck, Charles J. ;

Pandey, Suman ;

Wang, Ping ;

Goldenberg, Naila ;

Uppal, Muhammad ;

Khanal, Suraj .

TRANSLATIONAL RESEARCH, 2009, 153 (01) :11-16

[3] Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population [J].

Aksnes, Tonje A. ;

Kjeldsen, Sverre E. ;

Rostrup, Morten ;

Omvik, Per ;

Hua, Tsushung A. ;

Julius, Stevo .

HYPERTENSION, 2007, 50 (03) :467-473

[4]

ANAGNOSTIS P, 2010, CURR VASC PHARM

[5] Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Symeonidis, AN ;

Didangelos, TP ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Mikhailidis, DP .

ANGIOLOGY, 2003, 54 (06) :679-690

[6] The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Symeonidis, AN ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Elisaf, M .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734

[7] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[8] Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis [J].

Baker, William L. ;

Talati, Ripple ;

White, C. Michael ;

Coleman, Craig I. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (01) :98-107

[9] The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation [J].

Calkin, A. C. ;

Giunti, S. ;

Sheehy, K. J. ;

Chew, C. ;

Boolell, V. ;

Rajaram, Y. S. ;

Cooper, M. E. ;

Jandeleit-Dahm, K. A. .

DIABETOLOGIA, 2008, 51 (09) :1731-1740

[10]

CANNON CP, 2010, LANCET

← 1 2 3 4 5 6 →